Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma

Inclusion Criteria: * aged 18 year or older * diagnosed with locally advanced HCC without extra-hepatic metastases * HCC must not be amendable to treatment by surgical resection or percutaneous radiofrequency ablation * after assessment by the investigator and multidisciplinary tumor board, the patient is considered suitable for protocol treatment with Holmium-166 TARE * ECOG performance status 0-2 * child-Pugh A-B * tumor response evaluable with mRECIST criteria during follow-up Exclusion Criteria: * prior treatment with any of the following treatment modalities for HCC: systemic therapy, hepatic radiation therapy * currently enrolled in clinical studies where patient receive investigational therapeutic drug * metastatic disease * concurrent malignancy * active contra-indications to angiography or selective catherization (i.e. severe vascular disease or bleeding diathesis) * uncontrolled and/or severe comorbidities (active infection, heart failure,...) with limited estimated life expectancy * history of or know allergic reactions to used compounds